All In Biotech

NDA 018925 · Exela Pharma

Verapamil Hydrochloride

Verapamil Hydrochloride · Intravenous

Last checked: Nov 20, 2026Latest source record: Nov 18, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Mar 30, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

143

16 Phase 3, 13 recruiting

FAERS reports

4,312

3,916 serious, 958 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 26, 2024.

INDICATIONS & USAGE Verapamil is indicated for the treatment of supraventricular tachyarrhythmias, including: • Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to Verapamil administration. • Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation, except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes). In controlled studies in the U.S., about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous Verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in heart rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after Verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. The effect of a single injection lasts for 30–60 minutes when conversion to sinus rhythm does not occur. Because a small fraction (<1.0%) of patients treated with Verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation with an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole—see Contraindications and Warnings), the initial use of intravenous...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 30, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • VERAPAMIL HYDROCHLORIDE · VERAPAMIL HYDROCHLORIDE 10MG/4ML (2.5MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • VERAPAMIL HYDROCHLORIDE · VERAPAMIL HYDROCHLORIDE 5MG/2ML (2.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Verapamil" as an intervention, any sponsor and status, largest first.

All 143 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea357
  • nausea353
  • drug interaction316
  • dizziness293
  • hypotension287
  • fatigue277
  • diarrhoea271
  • abdominal pain245
  • vomiting244
  • cough242
  • headache238
  • fall237

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200482
2005130
2006122
200758
200890
200953
201086
201179
2012112
201361
2014109
2015160
2016187
2017187
2018199
2019217
2020243
2021273
2022488
2023407
2024438
2025331
2026200

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,740 on PubMed

Sponsor: Exela Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.